|Daily Range||$37.43 - $37.61|
|52-Week Range||$32.68 - $38.71|
|Dividend (Yield)||$0.00 (2.4%)|
|Average Daily Volume||991,079|
|Current FY EPS||$1.99|
This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.
This 3D bioprinting company finally has a product on the market.
Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.
Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.
Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.
Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.
ImmunoGen is among biotech's worst stocks in October after the company reports weaker-than-expected third quarter results. Find out if a rebound is in the cards.
PacBio was among the best performing healthcare stocks in October. Find out what lit a fire under its shares.
What investors need to know about Pacific Biosciences' third quarter performance.
A biotech stock running out of money is a very real concern for healthcare investors. With $317.3 million in an accumulated deficit since inception, does Inovio have enough cash to survive?.